3,4-二氯-[1,1-联苯]-3-羧酸 | 844878-91-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,4-二氯-[1,1-联苯]-3-羧酸
• 中文别名: 3',4'-二氯-3-联苯甲酸
• 英文名称: 3',4'-dichloro[1,1‘-biphenyl]-3-carboxylic acid
• 英文别名: 3',4'-dichloro[1,1'-biphenyl]-3-carboxylic acid；3-(3,4-dichlorophenyl)benzoic acid
• CAS: 844878-91-7
• 化学式: C₁₃H₈Cl₂O₂
• mdl: MFCD06201435
• 分子量: 267.111
• InChiKey: ZNGKPPXJOKCBBF-UHFFFAOYSA-N

物化性质

• 沸点：
  446.7±35.0 °C(Predicted)
• 密度：
  1.397±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(3,4-Dichlorophenyl)benzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(3,4-Dichlorophenyl)benzoic acid
CAS number: 844878-91-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H8Cl2O2
Molecular weight: 267.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,4-二氯-[1,1-联苯]-3-羧酸 在 4-二甲氨基吡啶 、 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 乙酸乙酯 、 甲苯 为溶剂， 反应 5.0h， 生成 3’-4’-dichloro-N-((4-(4-ethoxyphenoxy)phenyl)sulfonyl)[1,1’-biphenyl]-3-carboxamide
  参考文献：
  名称：

  Palladium-Mediated Site-Selective C–H Radio-iodination

  摘要：

  The palladium-mediated C-H radio-iodination of arenes using sodium iodide as the primary isotopic source is reported and performed without chemical know-how in 30 min and applied to the synthesis of complex radio-iodinated compounds of biological interest.

  DOI：

  10.1021/acs.orglett.8b02819
• 作为产物：
  描述：

  3,4-二氯苯硼酸 、 3-碘苯甲酸 在 palladium diacetate 、 sodium carbonate 、 三苯基膦 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 21.0h， 以4.4 g的产率得到3,4-二氯-[1,1-联苯]-3-羧酸
  参考文献：
  名称：

  Palladium-Mediated Site-Selective C–H Radio-iodination

  摘要：

  The palladium-mediated C-H radio-iodination of arenes using sodium iodide as the primary isotopic source is reported and performed without chemical know-how in 30 min and applied to the synthesis of complex radio-iodinated compounds of biological interest.

  DOI：

  10.1021/acs.orglett.8b02819

文献信息

• NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
  申请人：TECHNISCHE UNIVERSITÄT DRESDEN

  公开号：US20210130328A1

  公开（公告）日：2021-05-06

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及一种新型具有胸腺嘧啶骨架的化合物，这些化合物用于医药领域，特别是用于治疗癌症、HSP27相关疾病和囊性纤维化；以及含有至少一种这些化合物的药物产品。最后，提供了一种生产这些新型化合物的方法。这些化合物的一般化学式为式(I)，如权利要求书中进一步定义。
• COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
  申请人：Technische Universität Dresden

  公开号：EP3819006A1

  公开（公告）日：2021-05-12

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及作为具有胸腺嘧啶骨架的新化学实体的新型化合物，这些化合物可用于医药，特别是治疗癌症、HSP27 相关疾病和囊性纤维化；以及含有至少一种这些化合物的医药产品。最后，还介绍了一种生产这种新型化合物的方法。 这些化合物的通式为式（I）： 如权利要求 1 所进一步定义。
• Compounds with thymine skeleton for use in medicine
  申请人：TECHNISCHE UNIVERSITÄT DRESDEN

  公开号：US11214564B2

  公开（公告）日：2022-01-04

  The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.

  本发明涉及作为具有胸腺嘧啶骨架的新化学实体的新型化合物，这些化合物可用于医药，特别是治疗癌症、HSP27 相关疾病和囊性纤维化；以及含有至少一种这些化合物的医药产品。最后，还介绍了一种生产这种新型化合物的方法。 这些化合物的通式为式（I）： 如权利要求 1 所进一步定义。
• SAR by Interligand Nuclear Overhauser Effects (ILOEs) Based Discovery of Acylsulfonamide Compounds Active against Bcl-x_Land Mcl-1
  作者：Michele F. Rega、Bainan Wu、Jun Wei、Ziming Zhang、Jason F. Cellitti、Maurizio Pellecchia

  DOI：10.1021/jm200826s

  日期：2011.9.8

  Overexpression of antiapoptotic members of the Bcl-2 family proteins, such as Bcl-x(L), and Mfl-1, has been shown to be involved in resistance to chemotherapeutic drugs in many forms of cancers. Recent efforts from the Abbott Laboratories resulted in the development of the acylsulfonamide compound and clinical candidate that targets selectively Bcl-2, Bcl-x(L), and Bcl-w while it is not active against Mcl-1 and Bfl-1. However, early clinical and preclinical studies suggest that pan-Bcl-2 antagonists, targeting simultaneously Mcl-1, Bcl-x(L), and possibly all other four antiapoptotic Bcl-2 proteins, may result in more efficacious drugs. Here, following an NMR fragment-based approach, SAR by ILOEs, we report on compounds that exhibit nanomolar affinities for both Bcl-x(L) and Mcl-1 in vitro. We believe that these molecules can be used as useful starting point for the development of novel Bcl-2 antagonists, in particular targeting Mcl-1.
• MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE AND KETO-PIPERAZINE COMPOUNDS
  申请人：Palatin Technologies, Inc.

  公开号：EP1919479A2

  公开（公告）日：2008-05-14